Welcome to Greg Rowland’s Alzheimer’s Research Report, delivering clear, evidence-based breakdowns of emerging therapies and diagnostic breakthroughs.
Free Subscribers: Access the high-level executive summary below.
Paid Subscribers: Unlock the full analysis, deep dives into clinical trials, and data-backed takeaways.
Select an option below to support independent research and unlock full access:
Monthly Pass: $10/month — Full access to all current and archived reports.
Annual Pass: $100/year — Save $20 and secure uninterrupted insights.
Founder’s Circle: $250/year — Includes full access plus an exclusive monthly video roundtable discussing the latest therapeutic pipelines in detail.
SUMMARY
A new radiodiagnostic agent for positron emission tomography (PET) has been approved by the FDA. This new agent is designed specifically to bind to tau neurofibrillary tangles, offering key clinical advantages over traditional imaging methods.
The Full Report includes:
key clinical advantages TAUKLARIFY has over traditional imaging methods
quote from the President of EB USA, the developer of TAUKLARIFY
